Host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Steven E Nissen (Cleveland Clinic, Cleveland, OH, US) to discuss the results from the secondary analysis of the STRENGTH Trial.
The study assessed the long-term outcomes statin residual risk with epanova in high cardiovascular risk patients with hypertriglyceridemia.

Recorded remotely from Cleveland and Hamilton, 2021. 

Editor: Mirjam Boros